Brentuximab vedotin is an effective therapy for CD30+ mycosis fungoides and cutaneous anaplastic large-cell lymphoma: what is the cost?

Linked Article: Stranzenbach et al. Br J Dermatol 2017; 177:1503–1509.

http://ift.tt/2CFofvy